""No serious pharmaceutical company would pay even $5 million for this sad shell now."
C'mon, Spots. The AS approval, if it comes to that, will boost the whole IBD franchise, maybe even getting a purchase offer from AS. I don't see why you write off B for OM, it may be an adjuvant drug, it may not be, but it has a decent chance at getting through a Ph3 trial; and given the general failure of the competition even a modest success of a spit and swish with no huge SEs could be a good addition to every hospitals drug formulary as well as to most doctor's offices. Lots of bucks there and lots of happy patients undergoing chemo treatments. I've kind of written off the B for ABSSSI because Leo let it go dormant while the world shifted to antibiotic pills. But, if there is OM or IBD capital available, it would only take another treatment method to augment the facility based IV to add some value to B for ABSSSI. If none of this happens even $5 million will be out of reach. If it does, who knows. Maybe even Kevetrin, if there is money to test it out, but that is a future bet, for sure. It also calls for a wise CEO."
Unfortunately the small leak, LE, was never addressed. That little leak(er) did not bother to have the aged shingles replaced, which dampened and rotted the rafters , joists and studs. It's fed the termites and carpenter ants, but rendered the structure worthless.
